The shareholders of Xell AG, a specialist supplier of cell culture media, have sold their shares to Sartorius Stedim Biotech, a division of the listed life science company Sartorius.
Xell AG, based in Bielefeld, Germany, provides ultra-high-performance culture media and feeds in particular for the production of viral vectors used in gene therapies and vaccines, since its foundation 12 years ago. In addition, the globally operating company offers various analytical services to characterize and quantify media components and optimize media formulations. Two years ago, the company invested in a very extensive and state-of-the-art production facility for powder and liquid culture media.
Sartorius is a leading international partner of the biopharmaceutical industry and life science research sector. By acquiring complementary technologies, Sartorius AG regularly extends its portfolio in the areas of “Lab Products & Services” and “Bioprocess Solutions”. During 2020, the company generated revenues of approx. 2.3 billion euros. By the end of 2020 the group employed nearly 11,000 people in more than 110 countries.
“With its strong sales team and complementary product portfolio, Sartorius offers an excellent platform for further expansion, and we are looking forward to our joint future development very much. We would like to thank the IMAP team for their professional and spot-on advice in this exciting transaction process,” said Stefan Northoff, CEO of Xell AG.
The IMAP team consisting of Dr. Carsten Lehmann, Patrick Fritscher and Isabella Böing exclusively advised the shareholders of Xell AG and supported them in preparing, negotiating and successfully closing the transaction.